StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

BioLineRx cash

Cash and short-term investments held at the end of each period.

BioLineRx's cash was $4.63M at Jun 30, 2026. For fiscal 2025 it was $3.25M, down 68.9% from the year before. Over ten years it grew -5.2% a year on average. The highest annual figure on record is $16.83M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.25M-68.9%
FY2024Dec 31, 2024$10.44M+145.3%
FY2023Dec 31, 2023$4.26M-59.8%
FY2022Dec 31, 2022$10.59M-18.5%
FY2021Dec 31, 2021$12.99M-22.8%
FY2020Dec 31, 2020$16.83M+217.7%
FY2019Dec 31, 2019$5.30M+55.6%
FY2018Dec 31, 2018$3.40M-33.4%
FY2017Dec 31, 2017$5.11M+107.0%
FY2016Dec 31, 2016$2.47M-55.5%
FY2015Dec 31, 2015$5.54M-4.2%
FY2014Dec 31, 2014$5.79M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.63M-51.9%
Q4 FY2025Dec 31, 2025$3.25M-23.6%
Q2 FY2025Jun 30, 2025$7.19M-28.8%
Q4 FY2024Dec 31, 2024$10.44M-1.4%
Q2 FY2024Jun 30, 2024$9.62M-31.3%
Q4 FY2023Dec 31, 2023$4.26M-67.2%
Q2 FY2023Jun 30, 2023$10.10M-42.2%
Q4 FY2022Dec 31, 2022$10.59M-37.1%
Q2 FY2022Jun 30, 2022$14.00M+153.5%
Q4 FY2021Dec 31, 2021$12.99M+145.2%
Q2 FY2021Jun 30, 2021$17.48M+251.6%
Q4 FY2020Dec 31, 2020$16.83M+394.4%
Q2 FY2020Jun 30, 2020$5.52M-4.6%
Q4 FY2019Dec 31, 2019$5.30M+3.7%
Q2 FY2019Jun 30, 2019$4.97M-28.4%
Q4 FY2018Dec 31, 2018$3.40M+37.9%
Q2 FY2018Jun 30, 2018$5.79M+4.4%
Q4 FY2017Dec 31, 2017$5.11M-11.7%
Q2 FY2017Jun 30, 2017$6.95M–
Q4 FY2016Dec 31, 2016$2.47M–
Q4 FY2015Dec 31, 2015$5.54M–
Q4 FY2014Dec 31, 2014$5.79M–

More BioLineRx figures

See a number that looks wrong?